1. Home
  2. ATRA
  3. ATRA News

Latest Atara Biotherapeutics Inc. (ATRA) News on October 29, 2025

While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership
ATRA

Simply Wall St.

a month ago

While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
ATRA

Business Wire

5 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations
ATRA

Simply Wall St.

5 months ago

Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations

ATRA

Associated Press Finance

5 months ago

Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
ATRA

Business Wire

5 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering
ATRA

Business Wire

5 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

ATRA

MT Newswires

6 months ago

Atara Biotherapeutics Says FDA Lifts Clinical Hold on Ebvallo Investigational New Drug Applications

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
ATRA

Business Wire

6 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
ATRA

Zacks

8 months ago

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade

Atara Biotherapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ATRA

Simply Wall St.

8 months ago

Atara Biotherapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
ATRA

Zacks

8 months ago

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

ATRA

Associated Press Finance

8 months ago

Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
ATRA

Business Wire

8 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet
ATRA

Zacks

8 months ago

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

9 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Intellia makes progress on HAE study; 2 more China drug deals
ATRA

BioPharma Dive

9 months ago

Intellia makes progress on HAE study; 2 more China drug deals

ATRA

MT Newswires

9 months ago

Atara Biotherapeutics Shares Tumble After FDA Places Clinical Hold on Investigational New Drug Applications

ATRA

MT Newswires

9 months ago

Rodman & Renshaw Downgrades Atara Biotherapeutics to Neutral From Buy, $7 Price Target

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
ATRA

Benzinga

9 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
ATRA

Business Wire

9 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
ATRA

Zacks

9 months ago

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
ATRA

BioPharma Dive

9 months ago

Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs

ATRA

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise Thursday Afternoon

ATRA

MT Newswires

9 months ago

Top Midday Decliners

Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application
ATRA

GuruFocus.com

9 months ago

Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application

ATRA

MT Newswires

9 months ago

Atara Biotherapeutics Shares Tumble Amid 'Compliance Issues' Involving Manufacturing Plant for Ebvallo

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
ATRA

Business Wire

9 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
ATRA

Zacks

10 months ago

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Here's Why You Should Consider Buying Atara Biotherapeutics Stock
ATRA

Zacks

10 months ago

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last week
ATRA

Simply Wall St.

10 months ago

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last week

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
ATRA

Zacks

10 months ago

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why

ATRA

MT Newswires

10 months ago

Rodman & Renshaw Initiates Coverage on Atara Biotherapeutics With Buy Rating, $25 Price Target

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
ATRA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
ATRA

Simply Wall St.

a year ago

Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
ATRA

Zacks

a year ago

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

ATRA

Associated Press Finance

a year ago

Atara Biotherapeutics: Q3 Earnings Snapshot

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
ATRA

Zacks

a year ago

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

a year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATRA

GuruFocus.com

a year ago

Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

a year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ATRA

MT Newswires

a year ago

Top Midday Gainers

ATRA

MT Newswires

a year ago

Atara Biotherapeutics to Raise $36 Million From Direct Offering; Shares Soar After-Hours

Atara Biotherapeutics Announces $36 Million Registered Direct Offering
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
ATRA

Simply Wall St.

a year ago

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price

Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations
ATRA

Simply Wall St.

a year ago

Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
ATRA

Zacks

a year ago

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

ATRA

Associated Press Finance

a year ago

Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

US FDA grants priority review for Pierre Fabre’s EBV+ PTLD
ATRA

Pharmaceutical Technology

a year ago

US FDA grants priority review for Pierre Fabre’s EBV+ PTLD

FDA priority review advances Atara’s tabelecleucel for viral infection
ATRA

Pharmaceutical Technology

a year ago

FDA priority review advances Atara’s tabelecleucel for viral infection

ATRA

MT Newswires

a year ago

Atara Biotherapeutics Says Tab-Cel Biologics License Application Gets FDA Priority Review

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
ATRA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
ATRA

Zacks

a year ago

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

a year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
ATRA

Business Wire

a year ago

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
ATRA

Business Wire

a year ago

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
ATRA

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

a year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ATRA

Business Wire

a year ago

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
ATRA

Business Wire

a year ago

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
ATRA

Zacks

a year ago

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
ATRA

Zacks

a year ago

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

ATRA

MT Newswires

a year ago

Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
ATRA

Business Wire

a year ago

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
ATRA

Simply Wall St.

a year ago

Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
ATRA

Zacks

a year ago

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

ATRA

Associated Press Finance

a year ago

Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
ATRA

Business Wire

a year ago

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

a year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATRA

Business Wire

2 years ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
ATRA

Zacks

2 years ago

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

ATRA

Associated Press Finance

2 years ago

Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
ATRA

Business Wire

2 years ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
ATRA

Business Wire

2 years ago

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
ATRA

Business Wire

2 years ago

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
ATRA

Business Wire

2 years ago

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
ATRA

Simply Wall St.

2 years ago

After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
ATRA

Business Wire

2 years ago

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
ATRA

PR Newswire

2 years ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
ATRA

Zacks

2 years ago

Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
ATRA

PR Newswire

2 years ago

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
ATRA

GlobeNewswire

2 years ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

ATRA

Business Wire

2 years ago

AMTD Digital’s Entertainment and Movie Businesses Are Estimated to Contribute Significantly to Net Profit

BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Declares Monthly Distribution
ATRA

Business Wire

2 years ago

BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Declares Monthly Distribution

ATRA

Business Wire

2 years ago

AMTD Digital’s Half Yearly Net Profit is Estimated to Increase over 150% Year over Year

Charles Schwab Boosts Its Online Brokerage With Big TD Ameritrade Deal
ATRA

Investor's Business Daily

2 years ago

Charles Schwab Boosts Its Online Brokerage With Big TD Ameritrade Deal

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
ATRA

PR Newswire

2 years ago

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Canoo: Buy, Sell, or Hold?
ATRA

Motley Fool

2 years ago

Canoo: Buy, Sell, or Hold?

Schwab Earnings Beat Estimates. Why the Stock Is Dropping.
ATRA

Barrons.com

2 years ago

Schwab Earnings Beat Estimates. Why the Stock Is Dropping.

Canoo Delivered Electric Vehicles to Kingbee
ATRA

GlobeNewswire

2 years ago

Canoo Delivered Electric Vehicles to Kingbee

Loop Industries Reports Third Quarter Fiscal 2024 Results and Provides Updates on Business Developments
ATRA

ACCESSWIRE

2 years ago

Loop Industries Reports Third Quarter Fiscal 2024 Results and Provides Updates on Business Developments

Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Quarterly Distribution
ATRA

Business Wire

2 years ago

Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Quarterly Distribution

Share on Social Networks: